



AstraZeneca AB
 SE-151 85 Södertälje, Sweden
 T: +46 8 553 260 00
 F: +46 8 553 290 00
 astrazeneca.com

Product and Application Business Support (PA-BUS)
European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

18th February 2021

Confidential

Subject: Monthly Update for LEG002 -Legally Binding measure to Conditional Marketing
 Authorisation Application: COVID-19 Vaccine (ChAdOx1-S [recombinant]), 1 x 10¹¹vp/mL, suspension
 for injection

INN or Common Name:- COVID-19 Vaccine (ChAdOx1-S [recombinant])

MAH: AstraZeneca AB, SE-151 85 Södertälje , Sweden

Product reference: EMEA/H/C/005675

Dear Sir / Madam,

| Date | Submission Type | LEG002 | Document being provided | Status |
|------------------|-----------------|--|--|---------|
| 18 February 2021 | Monthly Update | For the root cause analysis (RCA) of the investigation into homogeneity of lot ABV3922, progress reports to be provided monthly from 18 February until resolution of the RCA investigation and any necessary corrective actions are agreed | Interim Investigation Report for deviation #154486 | Ongoing |

Reg Office AstraZeneca AB (publ)
 SE-151 85 Södertälje, Sweden
 Reg No 556011-7482



As committed in Legally Binding measure LEG002, *For the root cause analysis (RCA) of the investigation into homogeneity of lot ABV3922, progress reports to be provided monthly from 18 February until resolution of the RCA investigation and any necessary corrective actions are agreed.* The first progress report Interim Investigation Report for deviation #154486, Variable infectivity results obtained during RIVM testing of AZD1222, batch ABV3922 is being provided.

The objective of this report is to document AstraZeneca's investigation of this event including detailed root cause analysis (RCA), impact analysis and actions taken. On January 22, 2021 the National Institute for Public Health and the Environment (RIVM), The Netherlands, informed the AstraZeneca QPs of variable results obtained during government testing for AZD1222, batch ABV3922 manufactured at Catalent Anagni, Italy.

An in-depth investigation has taken place that consisted of :

- Extended additional testing of available samples from different sections of batch ABV3922.
- Extended additional absorbance testing of available samples from different sections of the batches manufactured after ABV3922.
- Detailed Root Cause Analysis evaluations performed by both Catalent Anagni and AstraZeneca using the Fishbone/Ishikawa and 5 Whys methodology.

The most probable root cause has been identified and is detailed in the investigation report. It can also be concluded that PPQ batches manufactured before ABV3922 (PPQ Batches) and AZD1222 batches manufactured after ABV3922 are not impacted by the event. The list of CAPAs will be defined and communicated as part of the final investigation report.

The next investigation report will be provided on or before 18 March 2021.

Please also note that a formal ECTD submission is not planned at this time but will be made upon request or at the proposed closure of the PAM.

Yours sincerely,

5.1.2e

5.1.2e

5.1.2e

AstraZeneca,

5.1.2e



Mob [REDACTED] 5.1.2e
Fax [REDACTED] 5.1.2e
E-mail: [REDACTED] 5.1.2e @astrazeneca.com

On behalf of AstraZeneca AB